Who else wanted to buy IvericIveric? Before the $5.9B Astellas deal, five biopharma companies took a look
2023-05-23
上市批准并购
Two years ago, as Iveric Bio went through late-stage studies of its main experimental drug, it began attracting interest from potential buyers. Five companies ended up in early-stage discussions with the biotech at the time, and others would express interest later on, though ultimately, only one would make a bid to buy it.
Iveric ended up striking a
$5.9 billion deal
with Astellas in April. An SEC filing details the run-up to the takeover, showing Astellas was the sole formal bidder on Iveric despite drawing general interest from a handful of biopharmas. Iveric’s key drug, called Zimura or avacincaptad pegol, is
up for an FDA approval decision in August
to treat geographic atrophy, a serious eye disease that can lead to blinding.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。